Optimising outpatient care in mild to moderate psoriasis by a newly developed Topical Treatment Optimising Programme - an international study using Daivobet/Dovobet Gel (PSO-TOP).

Trial Profile

Optimising outpatient care in mild to moderate psoriasis by a newly developed Topical Treatment Optimising Programme - an international study using Daivobet/Dovobet Gel (PSO-TOP).

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary) ; Betamethasone-dipropionate/calcipotriol (Primary) ; Betamethasone; Calcipotriol
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PSO-TOP
  • Most Recent Events

    • 16 Mar 2017 Results (n=1790) published in the British Journal of Dermatology.
    • 08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top